FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition in the form of a tablet with an erodible matrix, which contains one or more fumaric acid ethers, as well as a rate-controlling agent, representing hydroxypropylcellulose and a binding agent, representing lactose, with the decomposition of the said degradable matrix providing the controlled release of the said fumaric acid ether (ethers).
EFFECT: provision of the controlled release of fumaric acid ether (ethers).
19 cl, 43 ex, 2 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING ONE OR MORE ESTERS OF FUMARIC ACID IN A DECOMPOSABLE MATRIX | 2010 |
|
RU2743637C2 |
| FUMARIC ACID-BASE MICROTABLETS | 1999 |
|
RU2210366C2 |
| DOSAGE FORM IN CAPSULE FORM CONTAINING TABLETS WITH DIMETHYL FUMARATE | 2019 |
|
RU2742745C1 |
| DIMETHYL FUMARATE-CONTAINING ENTERIC TABLET | 2020 |
|
RU2786364C1 |
| STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING THYROID HORMONE RECEPTOR AGONISTS | 2007 |
|
RU2450810C2 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| MESALAZINE TABLET WITH IMPROVED SOLUBILITY | 2011 |
|
RU2610435C2 |
| ORAL PHARMACEUTICAL MEDICINAL FORM WITH DISCRETE RELEASE | 1998 |
|
RU2205028C2 |
| PHARMACEUTICAL COMPOSITIONS WITH DEFERRED RELEASE CONTAINING VALPROIC ACID AND THEIR USE | 2017 |
|
RU2760304C2 |
| THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT | 2006 |
|
RU2442574C2 |
